• Monday, Apr 12, 2021
  • Last Update : 09:56 pm

Drugmakers: Oral Covid-19 treatment yields promising trial data

  • Published at 09:30 am March 7th, 2021
File photo: Health workers are seen in protective gear inside a locked down portion of the Jordan residential area to contain a new outbreak of the coronavirus disease (Covid-19), in Hong Kong, China January 23, 2021 Reuters

Merck is also working on another oral Covid-19 treatment called MK-711

German pharmaceutical giant Merck and a US partner reported promising results Saturday in trials of a drug administered orally to fight Covid-19, saying it helps reduce patients' viral load. 

"At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data," said Wendy Painter, chief medical officer of the US firm, Ridgeback Biotherapeutics.

In January, Merck halted work on two Covid-19 vaccine candidates but has pressed on with research into two products to treat the disease, including a pill-based one called molnupiravir, which it has developed with Ridgeback Biotherapeutics. 

This drug caused a significant drop in patients' viral load after five days of treatment with it, Merck said at a meeting with infectious disease experts.

This Phase 2a test -- drug trials have three stages before a product can be approved -- was carried out among 202 non-hospitalized people with symptoms of Covid-19.

Also Read - Oxford study indicates AstraZeneca effective against Brazil variant

There was no alert in terms of safety, and of four serious adverse events that were reported, none were considered to be related to taking this drug, Ridgeback said. 

Anti-viral oral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) are sometimes prescribed for seasonal flu but researchers have yet to come up with something similar to fight the coronavirus.

The findings of this study -- a quicker decrease in viral load among individuals with early-stage Covid-19 who are treated with molnupiravir -- are promising, said William Fischer, lead investigator of the study and a professor of medicine at the University of North Carolina.

"If supported by additional studies, (they) could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally," Fischer added.

Merck is also working on another oral Covid-19 treatment called MK-711. 

Preliminary results from clinical trials with it show a more than 50% reduction in risk of death or respiratory trouble in patients hospitalized with moderate to severe Covid-19, the company said in January.

Facebook 54
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail